Maddi Hebebrand

The review found AD can disrupt family life, as caregiving responsibilities can lead to stress, guilt, and reduced opportunities for shared activities.

Researchers found two-thirds of patients reported no impact of psoriasis on their quality of life after 52 weeks of treatment with deucravacitinib.

Researchers emphasized the need for future studies to refine protocols and address economic barriers to combination therapy.

Swanson and Lockshin explored how PDE4 inhibitors improve quality of life for AD patients through targeted treatments that address both inflammation and chronic symptoms.

A recent review recognized the aesthetic concerns associated with GLP-1-induced weight loss and noted treatment options for various challenges.

Click here to answer today's poll and read more about practice management around the holiday season.

Michael Lewitt, MD, FAAD, highlighted the importance of personalized care, the decision-making process in psoriasis treatment, and the role of patient education.

Catch up on exclusive interviews with Christopher Bunick, MD, PhD; Raj Chovatiya, MD, PhD; and Alexander Egeberg, MD, PhD, from quarter 4 dermatologic conferences.

Hawkes shared his excitement for the near future of dermatology, recognizing the increasing ability to provide tailored care to patients.

The company stated INF904 disrupts inflammatory pathways with over 90% effectiveness, based on Phase 1 data.